Fully Funded Phase 4 Trials Necessary To Fill Knowledge Gaps On Malaria Vaccine Effectiveness

BBC News: Malaria vaccine: How good is good enough?
Seth Berkely, CEO of Gavi, the Vaccine Alliance, and Mark Dybul, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria

“How effective does a vaccine have to be before it should be made available? … Such is the question World Health Organization (WHO) experts will now be preparing to ask themselves as they consider whether or not to recommend the world’s first malaria vaccine for use in affected countries in Africa. … The best way to get any clarity on these issues is to see how the vaccine performs in a real-life setting, in high and low transmission areas, with and without high coverage of other interventions. … Currently, several phase four trials have been proposed for Mosquirix, some of which aim to shed more light on its effectiveness … yet none of these studies are fully-funded. That has to change. … Given the vast scale of the number of people affected, we have a duty to fill these gaps in our knowledge” (7/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.